Biogen
Trade Biogen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.
BIIB Key Statistics
BIIB News
Biogen (BIIB) shares are in focus after new clinical data showed extended improvements for Dravet syndrome patients taking zorevunersen. The findings, presented...
Biogen (BIIB) announced upcoming presentations from studies evaluating dapirolizumab pegol, a novel Fc-free anti-CD40L drug candidate, in systemic lupus erythem...
Tim Anderson, an analyst from Bank of America Securities, reiterated the Hold rating on Biogen. The associated price target remains the same with $167.00. Eleva...
Analyst ratings
51%
of 37 ratingsMore BIIB News
Florida-based wealth advisory J. L. Bainbridge & Co. sold 119,376 shares of Biogen (BIIB 0.58%) during the third quarter for an estimated $16.1 million. What H...
Eisai and Biogen announced in early October that the U.S. launch of LEQEMBI IQLIK, a subcutaneous autoinjector formulation for Alzheimer’s disease, has begun, w...